高h文Keep up with the latest news from CfPA, receive notifications about upcoming courses in your area of interest and more.
Overview and Current Status of Immunotherapy and CAR-T Cell Therapies
July 15, 2020 | 11:00 a.m.–12:30 p.m. (EDT)
Course Offering 2007903OL2786L
Course ID 2786
Who Should Attend?
This course is intended for individuals who work in the following industries:
- Health Technologies
- Clinical Trials
Professionals who would find this course beneficial include Engineers, Scientists, Formulators, Managers, Technicians, Investors, Clinicians, and Healthcare Professionals. It will be of interest to those who work in Research and Development, Manufacturing, Regulatory, Pre-Clinical and Clinical.
Lindsey Ott, PhD
Lindsey Ott, Ph.D.高h文, is a biomedical engineering in the Kansas City area specializing in developing cell therapies for human and animal health. She has five years of industry experience in drug discovery, cell-based assays, and cell therapies. Highlights from her career include serving as Director of Product Innovation at Likarda, LLC, a biotechnology and cell therapy company. She obtained her Ph.D. and postdoctoral training from the University of Kansas in Bioengineering with a focus in Biomaterials and Tissue Engineering. She has published and patented work in the fields of tracheal tissue engineering, biomaterial fabrication, adult mesenchymal stem cells for musculoskeletal tissue engineering, and preclinical drug discovery using 3D hepatic organoids. Her current work focused on developing cell-based assays for preclinical drug discovery, specifically in the areas of oncology, immunotherapies, and ADME-Tox.